Catalyst Pharmaceutical Partners Inc Stock
We can see a decrease in the price for Catalyst Pharmaceutical Partners Inc. Compared to yesterday it has lost -€0.190 (-1.340%).
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Catalyst Pharmaceutical Partners Inc.
With a target price of 24 € there is a hugely positive potential of 71.43% for Catalyst Pharmaceutical Partners Inc compared to the current price of 14.0 €.
Our community identified positive and negative aspects for Catalyst Pharmaceutical Partners Inc stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Catalyst Pharmaceutical Partners Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Catalyst Pharmaceutical Partners Inc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Catalyst Pharmaceutical Partners Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceutical Partners Inc | -1.340% | -0.491% | -6.522% | 22.645% | -8.687% | 193.667% | 320.756% |
| Ardelyx Inc. | -0.840% | -9.094% | -23.787% | 55.751% | -4.879% | -12.032% | - |
| Evolus Inc | - | -9.906% | -21.074% | 42.537% | 5.525% | -10.748% | - |
| Brainstorm Cell | -1.290% | -12.876% | -27.888% | -82.925% | 56.034% | -88.896% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-16
Catalyst Pharma (CPRX) appears to be fundamentally improving its financial position, owing to the growth seen in recent financial statements. Observing the company's financials, the trend of increasing revenues, net income, total assets, and shareholder's equity is noticeable. This indicates that Catalyst Pharma has been experiencing a growth phase in its business operations in the market.
*Pros: *
Revenue Growth: The company is experiencing substantial growth in total revenue from 2020 to 2022, which is positive for its financial position. This revenue growth is attributed to the company's ability to successfully market and sell its products, positively reflecting its business operations.
Comments
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $29.00 price target on the stock.
Show more
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Show more
Ratings data for CPRX provided by MarketBeat